logo

For the Inventor, By the Inventor

Hatfield, PA, United States of America

Suresh K Balani

This inventor holds 10 USPTO granted patents. Top assignee: Merck + Co., Inc.. Active years: 1992-2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Suresh K Balani. Retrieved from https://idiyas.com/inventor/suresh-k-balani

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10

% Patents Active = 100.0

Average Co-Inventor Count = 3.1

ph-index = 6

Forward Citations = 183(Granted Patents)


Company Filing History:

goldMedal10 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1992-2000

Loading Chart...
10 patents (USPTO):Explore Patents
1. 6147078 - Pyrazinone thrombin inhibitors (2000-11-14),
2. 5952347 - Quinoline leukotriene antagonists (1999-09-14),
3. 5527819 - Inhibitors of HIV reverse transcriptase (1996-06-18),
4. 5387512 - Preparation of (1995-02-07),
5. 5364776 - Method of hydroxylating (1994-11-15),
6. 5202243 - Method of hydroxylating (1993-04-13),
7. 5200329 - Method of hydroxylating (1993-04-06),
8. 5192668 - Synthesis of protease inhibitor (1993-03-09),
9. 5188950 - Method of preparing HIV protease inhibitors (1993-02-23),
10. 5169769 - Method of hydroxylating substituted 3-aminopyridinones using mammalian (1992-12-08),

Title: Suresh K Balani: Innovator in Thrombin Inhibitors and Leukotriene Antagonists

Introduction

Suresh K Balani is a prominent inventor based in Hatfield, PA, known for his significant contributions to the field of pharmaceuticals. He holds a total of 10 patents, showcasing his innovative spirit and dedication to advancing medical science.

Latest Patents

Among his latest patents, Balani has developed pyrazinone thrombin inhibitors. These compounds are designed to inhibit thrombin and address associated thrombotic occlusions. Another notable invention is his work on quinoline leukotriene antagonists. These compounds serve as antagonists to the actions of leukotrienes and are beneficial in treating various conditions, including asthma, allergies, inflammation, and more.

Career Highlights

Suresh K Balani is currently associated with Merck & Company, Inc., where he continues to push the boundaries of pharmaceutical research. His work has had a profound impact on the development of new therapeutic agents.

Collaborations

Throughout his career, Balani has collaborated with esteemed colleagues, including Byron H Arison and Harri G Ramjit. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Suresh K Balani's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a key innovator. His work continues to influence the development of important medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…